Eli Lilly – News Stories About Eli Lilly - Page 2

Eli Lilly to Pay $1.4B, Plead Guilty in Marketing Scheme

Jan 15, 2009 3:50 PM CST

Eli Lilly to Pay $1.4B, Plead Guilty in Marketing Scheme

Company promoted drug for unapproved uses

(Newser) - Eli Lilly will plead guilty to a federal misdemeanor and pay $1.42 billion to settle investigations into its marketing of an anti-schizophrenia drug, Reuters reports. The company promoted Zyprexa to the elderly as an anti-dementia pharmaceutical, though studies questioned its effectiveness in treating Alzheimer’s. “Eli Lilly had...

Stocks Skid on Jobs Numbers

MARKET Open

Dec 11, 2008 8:52 AM CST

Stocks Skid on Jobs Numbers

(Newser) - Stocks dipped at the open today, thanks to a sharp jump in jobless claims and more negative corporate news. The Dow fell 119 points, while the S&P and Nasdaq dropped 1.2% and 1.5% respectively, after the Labor Department announced that new unemployment claims hit a 26-year high...

Polly Want a Prozac?

Feb 26, 2008 9:33 AM CST

Polly Want a Prozac?

Parrots are the latest pets to see spike in depression

(Newser) - With more pet owners working long days and leaving their furry and feathered friends alone at home, cases of animal depression are on the rise, writes the Daily Telegraph. A TV vet says the trend is hitting parrots especially hard, causing the talkative birds to pull out their feathers or...

Antidepressants Mostly Useless, Study Finds

Feb 26, 2008 7:41 AM CST

Antidepressants Mostly Useless, Study Finds

Prozac and others make a difference only in most extreme cases

(Newser) - Big Pharma swallowed a bitter pill yesterday as Prozac and other antidepressants were found in a UK study to be largely ineffectual in all but the most extreme cases of depression. The meta-analysis of 47 clinical trials submitted to the FDA with licensing applications for six popular antidepressants concluded that...

Eli Lilly Could Pay $1B Settlement

Jan 30, 2008 5:40 PM CST

Eli Lilly Could Pay $1B Settlement

Fine for illegally promoting antipsychotic drug Zyprexa would be biggest ever

(Newser) - Drug-maker Eli Lilly could pay more than $1 billion to state and federal authorities to settle an investigation into how the company marketed an antipsychotic drug, the New York Times reports. In 2000-03, Lilly pushed doctors to prescribe Zyprexa as a treatment for age-related dementia—though the drug is approved...

FDA Mandates Suicide Risk Assessment in Drug Trials

Jan 24, 2008 11:42 AM CST

FDA Mandates Suicide Risk Assessment in Drug Trials

Danger doesn't lie only in antidepressants

(Newser) - The Food and Drug Administration is now requiring drug companies to monitor suicide warning signs in clinical trials for experimental drugs, the New York Times reports. In the wake of studies showing that antidepressants might increase the risk of self-harm in children and teens, the agency is showing an awareness...

Big Pharma Faces Big Plunge

Dec 6, 2007 4:50 AM CST

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic...

Pooch Prozac
Is Just the Start

Oct 6, 2007 8:13 AM CDT

Pooch Prozac Is Just the Start

New focus on depression and anxiety in pets, from dogs all the way down to fish

(Newser) - With Eli Lilly rolling out a chewable, beef-flavored version of its anti-depressant Prozac for dogs whose ears are drooping, the London Times looks at the current thinking on depression and anxiety in pets. Vets say dogs, as pack animals, are prone to separation anxiety, when left alone, and depression, when...

Schizophrenia Drug Offers
New Hope

Sep 3, 2007 3:58 AM CDT

Schizophrenia Drug Offers New Hope

Works on different brain chemical than its predecessors

(Newser) - The first human trial of a new medication to treat schizophrenia that works fundamentally differently from its predecessors has shown promising results, according to this month's Nature Medicine. The drug targets glutamate rather than dopamine, as do other drugs. Scientists have long known glutamate is involved in schizophrenia.